• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of essential thrombocythaemia by alpha 2a interferon.

作者信息

Bellucci S, Harousseau J L, Brice P, Tobelem G

出版信息

Lancet. 1988 Oct 22;2(8617):960-1. doi: 10.1016/s0140-6736(88)92625-6.

DOI:10.1016/s0140-6736(88)92625-6
PMID:2902403
Abstract
摘要

相似文献

1
Treatment of essential thrombocythaemia by alpha 2a interferon.α2a干扰素治疗原发性血小板增多症
Lancet. 1988 Oct 22;2(8617):960-1. doi: 10.1016/s0140-6736(88)92625-6.
2
Treatment of essential thrombocythaemia with interferon alpha-2b.α-2b干扰素治疗原发性血小板增多症
Lancet. 1989 Jan 14;1(8629):96. doi: 10.1016/s0140-6736(89)91446-3.
3
Maintenance therapy in the myeloproliferative disorders: the current options.骨髓增殖性疾病的维持治疗：当前的选择。
Br J Haematol. 1991 Oct;79 Suppl 1:92-5. doi: 10.1111/j.1365-2141.1991.tb08130.x.
4
Alpha-interferon therapy for essential thrombocythaemia.
Lancet. 1988 Jul 9;2(8602):70-2. doi: 10.1016/s0140-6736(88)90005-0.
5
Therapeutic effect of human recombinant interferon-alpha-2C in essential thrombocythaemia.重组人α-2C干扰素治疗原发性血小板增多症的疗效
Oncology. 1985;42 Suppl 1:10-4. doi: 10.1159/000226078.
6
Recombinant alpha-2a interferon (alpha-IFN) in the treatment of essential thrombocythaemia. Preliminary report.重组α-2a干扰素（α-干扰素）治疗原发性血小板增多症。初步报告。
Haematologica. 1987 May-Jun;72(3):277-9.
7
Alpha interferon raises serum beta-2-microglobulin in patients treated for thrombocythaemia.α干扰素可使接受血小板增多症治疗的患者血清β2-微球蛋白升高。
Br J Haematol. 1993 Jun;84(2):353-5. doi: 10.1111/j.1365-2141.1993.tb03082.x.
8
alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis.α干扰素治疗原发性血小板增多症及其他伴有血小板过度增多的骨髓增殖性疾病。
Eur J Cancer. 1991;27 Suppl 4:S69-71. doi: 10.1016/0277-5379(91)90578-2.
9
Interferon alpha-2a to control thrombocytosis in chronic myelogenous leukemia and essential thrombocythemia.
Asian Pac J Allergy Immunol. 1989 Dec;7(2):103-5.
10
Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.重组干扰素α-2C治疗：骨髓增殖性疾病中的多发性骨髓瘤和血小板增多症
Oncology. 1985;42 Suppl 1:19-25. doi: 10.1159/000226080.

引用本文的文献

1
TYK2 is essential for the therapeutic effect of IFN-α in V617F-induced murine myeloproliferative neoplasms.酪氨酸激酶2（TYK2）对于α干扰素（IFN-α）在V617F诱导的小鼠骨髓增殖性肿瘤中的治疗效果至关重要。
Blood Neoplasia. 2025 Mar 3;2(3):100087. doi: 10.1016/j.bneo.2025.100087. eCollection 2025 Aug.
2
Pegylated interferon: the who, why, and how.聚乙二醇化干扰素：适用人群、作用原理及使用方法
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):535-540. doi: 10.1182/hematology.2024000577.
3
Recent advances in therapies for primary myelofibrosis.
原发性骨髓纤维化治疗的最新进展
Fac Rev. 2023 Sep 26;12:23. doi: 10.12703/r/12-23. eCollection 2023.
4
Biology and therapeutic targeting of molecular mechanisms in MPNs.骨髓增殖性肿瘤中分子机制的生物学和治疗靶向。
Blood. 2023 Apr 20;141(16):1922-1933. doi: 10.1182/blood.2022017416.
5
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.骨髓增殖性肿瘤（MPN）：疾病起始、进展和转化的分子驱动因素及其对治疗的影响。
Cells. 2020 Aug 14;9(8):1901. doi: 10.3390/cells9081901.
6
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.免疫检查点阻断增强了针对骨髓增殖性肿瘤中突变钙网蛋白的共享新抗原诱导的 T 细胞免疫。
Cancer Discov. 2019 Sep;9(9):1192-1207. doi: 10.1158/2159-8290.CD-18-1356. Epub 2019 Jul 2.
7
Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α.高危 BCR/ABL 阴性骨髓增殖性肿瘤患者接受重组人干扰素-α治疗后出现抗干扰素-α抗体。
Med Sci Monit. 2018 Apr 17;24:2302-2309. doi: 10.12659/MSM.907876.
8
Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.平均血小板体积（MPV）升高是原发性和继发性骨髓纤维化患者生存预后较差的独立预测指标。
Int J Hematol. 2018 Feb;107(2):166-172. doi: 10.1007/s12185-017-2348-4. Epub 2017 Oct 11.
9
Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.干扰素疗法在骨髓增殖性肿瘤中的当代应用
Curr Hematol Malig Rep. 2017 Oct;12(5):406-414. doi: 10.1007/s11899-017-0402-1.
10
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.干扰素-α治疗骨髓增殖性肿瘤：靶向恶性克隆。
Leukemia. 2016 Apr;30(4):776-81. doi: 10.1038/leu.2015.326. Epub 2015 Nov 25.